Human albumin market set for steady growth as chronic disease demand rises

The global human albumin market is expanding as more patients need plasma-based therapy for surgery, burns, trauma and chronic disease management. North America led the market in 2025, while Asia-Pacific is expected to grow fastest as healthcare capacity and disease burden increase.

Why it matters: - Human albumin is used in critical care, surgery and dialysis, so demand tracks directly with hospital activity and chronic disease burden. - The market matters for patients with hypovolemia, hypoalbuminemia, burns, acute respiratory distress syndrome and kidney disease. - Growth in recombinant albumin and new formulations could change how hospitals source and use albumin products.

What happened: - The Business Research Company released a new human albumin market report covering market size, growth drivers, regional trends and leading competitors. - The report says the human albumin market has grown steadily and is expected to keep expanding. - The report highlights a free sample and the full report.

The details: - Human albumin is a protein in blood plasma that helps maintain oncotic pressure and transports hormones, enzymes, drugs and other molecules. - Clinicians administer albumin intravenously from pooled human plasma. - Common uses include treatment of hypovolemia, hypoalbuminemia, burns and acute respiratory distress syndrome. - Albumin is also used during liver transplants and dialysis to restore blood volume and stabilize circulation. - The report links market growth to more surgical procedures, broader plasma volume replacement use, more burns and trauma cases, and the established safety profile of plasma-derived albumin. - Rising dialysis patient volumes are adding to demand. - Future growth is expected from more critical care facilities, higher liver disease prevalence, greater use of recombinant albumin, improved plasma collection systems and more pharmaceutical formulations containing albumin. - The report identifies increased use in critical care, broader liver-related applications and a shift toward recombinant products as major trends. - Human albumin also supports fluid replacement and shock management because of its molecular binding capability. - The report says chronic disease prevalence is a primary driver, including conditions linked to aging, sedentary behavior, unhealthy diets and stress. - Human albumin plays a role in chronic kidney disease care by addressing hypoalbuminemia and helping maintain fluid balance. - A June 2023 Kidney Research UK report said about 7.2 million people in the UK, more than 10% of the population, live with chronic kidney disease. - Kidney Research UK estimated 3.25 million of those patients are in severe stages and 3.9 million are in early, often undiagnosed stages. - The same report projects the UK chronic kidney disease population will reach 7.61 million by 2033. - In 2025, North America was the largest regional market for human albumin. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market outlook is being shaped by two forces at once: more patients who need albumin now, and a product mix that is gradually shifting toward recombinant alternatives. - North America’s lead suggests strong clinical adoption and healthcare capacity, while Asia-Pacific’s growth points to expanding access and a rising disease burden. - The report’s focus on TAM analysis, company scoring matrices and market-hotspot graphics signals a more strategy-oriented sales pitch to industry buyers.

What's next: - The Business Research Company expects continued expansion as critical care capacity grows and albumin use broadens in liver disease and dialysis settings. - Market attention will likely stay on recombinant albumin, plasma supply systems and new formulation opportunities. - The report says its 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and updated trend visuals.

The bottom line: - Human albumin remains a core hospital therapy, and rising chronic disease rates are set to keep demand growing across major global markets.